Genus plc (GENSF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Genus plc (GENSF) trades at $31.07 with AI Score 52/100 (Grade B). Genus plc is an animal genetics company focused on pork and beef production. Market cap: $2.06B, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for GENSF: GENSF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GENSF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
GENSF: 3/6 perspectives are bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Genus plc (GENSF) Healthcare & Pipeline Overview
Genus plc, an animal genetics company, enhances pork and beef production through its PIC and ABS segments. Operating globally, the company provides genetically superior breeding stock and technical services, leveraging research and development to improve animal traits and productivity in the agricultural sector, with a current P/E ratio of 29.4.
What Is the Investment Thesis for GENSF?
Genus plc presents a compelling investment case based on its leading position in the animal genetics market and its focus on improving livestock productivity. The company's strong gross margin of 100.1% reflects its pricing power and the value of its genetic products. Growth is expected to be driven by increasing demand for animal protein globally and the adoption of advanced genetics to enhance farm efficiency. However, investors should be aware of the risks associated with animal health, regulatory changes, and competition. The company's beta of 0.85 suggests lower volatility compared to the overall market. With a market capitalization of $2.06B and a dividend yield of 1.23%, Genus plc offers a blend of growth and income potential.
Based on FMP financials and quantitative analysis
GENSF Key Highlights
- Market Cap of $2.06B, reflecting its significant presence in the animal genetics market.
- P/E ratio of 29.4, indicating investor expectations for future earnings growth.
- Gross Margin of 100.1%, showcasing the company's strong pricing power and efficient operations.
- Profit Margin of 7.1%, demonstrating the company's ability to convert revenue into profit.
- Dividend Yield of 1.23%, providing a steady income stream for investors.
Who Are GENSF's Competitors?
GENSF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BOEUF Bonesupport Holding AB (publ) | $21.40 | +0.00% | $1.41B | 51 |
| BRCTF BioArctic AB (publ) | $35.00 | +0.00% | $3.11B | 51 |
| CSPHF CStone Pharmaceuticals | $0.69 | +16.81% | $1.11B | 50 |
| GRRMF Gerresheimer AG | $30.73 | +0.00% | $1.06B | 43 |
| GTBIF Green Thumb Industries Inc. | $7.16 | -5.79% | $1.66B | 57 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GENSF's Key Strengths?
- Leading position in the animal genetics market.
- Strong brand reputation and customer relationships.
- Global distribution network.
- Proprietary genetic technologies.
What Are GENSF's Weaknesses?
- Exposure to animal health risks and disease outbreaks.
- Dependence on regulatory approvals.
- Potential for competition from generic genetic solutions.
- Sensitivity to economic cycles and commodity prices.
What Could Drive GENSF Stock Higher?
- Expansion into new geographic markets, particularly in Asia and Latin America.
- Development and launch of new genetic products and services.
- Potential acquisitions or partnerships to expand product portfolio and market reach.
- Increasing demand for sustainable livestock production solutions.
- Regulatory approvals for new genetic technologies.
What Are the Key Risks for GENSF?
- Rich valuation — a P/E of 29.4 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Animal health risks and disease outbreaks.
- Changes in consumer preferences and ethical concerns.
- Increased regulatory scrutiny and compliance costs.
- Competition from existing and new players in the animal genetics market.
- Economic cycles and commodity price volatility.
What Are the Growth Opportunities for GENSF?
- Expansion in Emerging Markets: Genus plc has a significant opportunity to expand its presence in emerging markets, particularly in Asia and Latin America, where demand for animal protein is rapidly increasing. These regions offer substantial growth potential for the company's PIC and ABS segments, as farmers seek to improve the productivity and efficiency of their livestock operations. The timeline for realizing this growth is ongoing, with continuous efforts to establish partnerships and distribution networks in these markets. This expansion can significantly increase revenue and market share.
- Adoption of Advanced Genetic Technologies: Genus plc can drive growth by investing in and adopting advanced genetic technologies, such as gene editing and CRISPR, to develop animals with improved traits, such as disease resistance, feed efficiency, and meat quality. These technologies have the potential to revolutionize animal breeding and create significant value for farmers and consumers. The timeline for realizing the benefits of these technologies is medium-term, with ongoing research and development efforts. The market size for gene-edited livestock is projected to grow significantly in the coming years.
- Strategic Acquisitions and Partnerships: Genus plc can pursue strategic acquisitions and partnerships to expand its product portfolio, geographic reach, and technological capabilities. Acquiring companies with complementary technologies or market access can accelerate growth and enhance the company's competitive position. The timeline for such acquisitions is opportunistic, depending on market conditions and available targets. Strategic partnerships can also provide access to new markets and technologies without the need for significant capital investment.
- Focus on Sustainable Livestock Production: Genus plc can capitalize on the growing demand for sustainable livestock production by developing and marketing genetic solutions that improve animal welfare, reduce environmental impact, and enhance resource efficiency. This includes breeding animals that require less feed, produce less waste, and are more resistant to diseases. The timeline for this growth is ongoing, with increasing consumer awareness and demand for sustainable products. The market for sustainable livestock production is expanding rapidly, driven by consumer preferences and regulatory pressures.
- Development of Novel Products and Services: Genus plc can drive growth by developing novel products and services that address unmet needs in the animal genetics market. This includes developing new genetic markers for predicting animal performance, offering advanced reproductive technologies, and providing data-driven insights to help farmers optimize their operations. The timeline for this growth is medium-term, with ongoing research and development efforts. The market for innovative animal genetics solutions is substantial, as farmers seek to improve their profitability and sustainability.
What Opportunities Does GENSF Have?
- Expansion in emerging markets.
- Adoption of advanced genetic technologies.
- Strategic acquisitions and partnerships.
- Growing demand for sustainable livestock production.
What Threats Does GENSF Face?
- Changes in consumer preferences and ethical concerns.
- Increased regulatory scrutiny.
- Emergence of new competitors.
- Disruptions to the global supply chain.
What Are GENSF's Competitive Advantages?
- Proprietary genetic technologies and intellectual property.
- Established brand reputation and customer relationships.
- Global distribution network and market access.
- Significant investment in research and development.
- High switching costs for customers due to the long-term nature of genetic improvement.
What Does GENSF Do?
Genus plc, established in 1994 and based in Basingstoke, UK, is a leading animal genetics company operating worldwide. It focuses on enhancing the productivity of livestock farming through genetic improvement. The company operates through three primary segments: Genus PIC, Genus ABS, and Genus Research and Development. Genus PIC specializes in porcine genetics, selling breeding pigs and semen designed to produce pork with desirable characteristics. Genus ABS focuses on bovine genetics, offering bull semen and embryos to improve milk and beef production. These products are marketed under the ABS, Genus, and Bovec brands. Genus also provides technical services to support farmers in optimizing their operations. With a global presence spanning North America, Latin America, Europe, the Middle East, Russia, Africa, and Asia, Genus plc plays a crucial role in the animal protein supply chain, continually investing in research and development to drive genetic advancements and improve the efficiency and sustainability of livestock farming.
What Products and Services Does GENSF Offer?
- Develop and market genetically superior breeding pigs under the PIC brand.
- Provide bull semen and embryos to improve milk and beef production under the ABS, Genus, and Bovec brands.
- Offer technical services to farmers to optimize their livestock operations.
- Conduct research and development to advance animal genetics and improve livestock traits.
- Operate globally, serving customers in North America, Latin America, Europe, the Middle East, Russia, Africa, and Asia.
- Focus on enhancing the productivity, efficiency, and sustainability of livestock farming.
How Does GENSF Make Money?
- Sales of breeding pigs and semen to pork producers.
- Sales of bull semen and embryos to dairy and beef farmers.
- Provision of technical services to support livestock operations.
- Investment in research and development to improve animal genetics.
What Industry Does GENSF Operate In?
Genus plc operates within the animal genetics industry, which is driven by the increasing global demand for animal protein and the need for efficient and sustainable livestock production. The industry is characterized by ongoing advancements in genetic technologies, such as gene editing and reproductive technologies, which are aimed at improving animal health, productivity, and welfare. Genus plc competes with companies like BOEUF, BRCTF, CSPHF, GRRMF and GTBIF, focusing on specific segments of the animal genetics market. The industry is subject to regulatory oversight and is influenced by consumer preferences and ethical considerations related to animal welfare.
Who Are GENSF's Key Customers?
- Pork producers seeking to improve the quality and efficiency of their operations.
- Dairy farmers aiming to increase milk production and improve herd health.
- Beef farmers looking to enhance meat quality and reduce production costs.
- Livestock farmers in emerging markets seeking to improve their productivity.
FY2027 estForward Outlook
Wall Street analysts project Genus plc revenue of about $683.4M for fiscal 2027, with EPS near $1.02. The estimate reflects 8 contributing analysts.
GENSF Valuation & Market Position
With a $2.06B market cap, Genus plc sits in the mid-cap segment of the market. Relative to its peer group, GENSF's quantitative score of 52/100 is roughly in line with the peer average of 50/100.
ROE 10%Key Financial Metrics
Return on equity for Genus plc stands at 9.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.2%, showing how much profit it generates from its asset base. GENSF trades at a trailing price-to-earnings ratio of 29.41, above the Healthcare sector average of ~23x. Its free cash flow yield is 4.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.25 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.3%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 7/9Financial Health
Genus plc's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 4.61 places it in the safe zone, indicating low near-term bankruptcy risk.
Company Profile
Genus plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Basingstoke, GB. The company is led by CEO Jorgen Kokke. GENSF has traded publicly since 2009.
GENSF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Genus's future prospects, indicating that key stakeholders believe in the company's growth potential.
- Community sentiment has turned positive, with discussions highlighting Genus's innovative breeding technologies as a key driver for long-term success.
- Analysts have noted strong demand in the livestock sector, which is expected to benefit Genus's market position and revenue streams.
- The company’s commitment to sustainability aligns well with current market trends, enhancing its appeal to socially conscious investors.
Bear Case
- Concerns over regulatory changes in agricultural practices could pose risks to Genus's operations and profitability.
- Market sentiment has seen fluctuations, with some community members expressing skepticism about the scalability of Genus's technologies.
- Recent comparisons to competitors reveal potential weaknesses in Genus's market share, raising questions about its competitive edge.
- Economic uncertainties in the agriculture sector may limit investment and growth opportunities for Genus in the near term.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
GENSF Latest News
No recent news available for GENSF.
GENSF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GENSF.
Price Targets
Wall Street price target analysis for GENSF.
GENSF MoonshotScore
What does this score mean?
The MoonshotScore rates GENSF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jorgen Kokke
CEO
Jorgen Kokke is the Chief Executive Officer of Genus plc, leading a global team of 3,500 employees. His background includes extensive experience in the animal health and genetics industry. He has held various leadership positions in multinational corporations, focusing on strategic planning, operational excellence, and business development. Kokke's expertise spans across different geographies and market segments, providing him with a comprehensive understanding of the global animal protein supply chain. His leadership is focused on driving innovation, enhancing customer value, and delivering sustainable growth for Genus plc.
Track Record: Under Jorgen Kokke's leadership, Genus plc has focused on expanding its global presence and investing in research and development to drive genetic advancements. Key achievements include strengthening the company's market position in emerging markets and launching innovative products that improve livestock productivity and sustainability. His strategic decisions have focused on enhancing customer value and delivering long-term growth for shareholders.
GENSF OTC Market Information
Genus plc trades on the OTC Other tier, which represents the lowest tier of the OTC market. Companies in this tier often have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. This tier typically includes companies with speculative business models, penny stocks, or those facing financial distress. Investing in OTC Other stocks carries significantly higher risks compared to exchange-listed securities due to the lack of regulatory oversight and transparency. Investors should exercise extreme caution and conduct thorough due diligence before considering an investment in GENSF.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Higher potential for fraud and manipulation.
- Lower liquidity and wider bid-ask spreads.
- Greater price volatility.
- Lack of regulatory oversight.
- Verify the company's financial statements and audit reports.
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Understand the company's capital structure and ownership.
- Monitor news and filings for any red flags or material events.
- Consult with a qualified financial advisor.
- Established operating history in the animal genetics industry.
- Global presence and customer base.
- Investment in research and development.
- Membership in industry associations.
- Positive media coverage and analyst reports (if available).
What Investors Ask About Genus plc (GENSF) — Healthcare
What does Genus plc do?
Genus plc is an animal genetics company that focuses on improving the productivity and efficiency of livestock farming. The company develops and markets genetically superior breeding pigs and cattle, providing semen, embryos, and technical services to pork, dairy, and beef producers worldwide. Genus plc operates through its PIC and ABS segments, leveraging research and development to enhance animal traits and contribute to a more sustainable and efficient animal protein supply chain. The company's products and services help farmers improve animal health, reduce production costs, and meet the growing global demand for animal protein.
What do analysts say about GENSF stock?
Analyst coverage of GENSF may be limited due to its OTC listing. However, the general sentiment towards Genus plc is influenced by its position in the animal genetics market and its growth prospects. Key valuation metrics to consider include the P/E ratio, gross margin, and dividend yield. Growth considerations include the company's expansion in emerging markets, adoption of advanced genetic technologies, and focus on sustainable livestock production. Investors should conduct their own research and consider the risks associated with investing in OTC stocks before making any investment decisions. Analyst consensus data is not readily available due to the stock's OTC status.
What are the main risks for GENSF?
Investing in GENSF carries several risks, including animal health risks such as disease outbreaks, which can significantly impact the company's operations and financial performance. Regulatory changes and increased scrutiny can also pose challenges. Competition from other animal genetics companies and the potential for generic genetic solutions can erode market share. Economic cycles and commodity price volatility can affect demand for the company's products and services. Additionally, as an OTC-listed stock, GENSF is subject to greater price volatility and liquidity risks compared to exchange-listed securities. Investors should carefully consider these risks before investing.
How does Genus plc navigate regulatory approval processes?
Genus plc is subject to regulatory oversight from bodies governing animal health, food safety, and genetic engineering. Navigating these processes involves rigorous testing, documentation, and compliance with international standards. The company actively engages with regulatory agencies to ensure its products meet safety and efficacy requirements. While specific details on pending approvals are unavailable, Genus plc's commitment to regulatory compliance is evident in its established operating history and global presence. This proactive approach helps mitigate risks associated with regulatory hurdles and ensures market access for its products.
How does Genus plc manage patent expiration risks?
Genus plc manages patent expiration risks by continuously investing in research and development to develop new and improved genetic solutions. The company also employs a multi-faceted intellectual property strategy, including patents, trademarks, and trade secrets, to protect its innovations. By maintaining a robust pipeline of new products and technologies, Genus plc can mitigate the impact of patent expirations and maintain its competitive advantage. The company also seeks to extend the lifecycle of its existing products through continuous improvement and innovation. Specific details on patent cliff exposure are not available in the provided data.
What are the key factors to evaluate for GENSF?
Genus plc (GENSF) holds an AI score of 52/100 (moderate). P/E: 29.4x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does GENSF data refresh on this page?
GENSF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GENSF's recent stock price performance?
Genus plc (GENSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Leading position in the animal genetics market. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be less reliable than exchange-listed data.
- Analyst coverage may be limited due to OTC listing.
- Financial data is based on available information and may not be complete.